Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL11401135 | 0.98 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL6656992 | 0.84 | SMN1; SMN2 (0.44) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL2632919 | 0.82 | MEN1 (0.57) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL11243798 | 0.78 | KMT2A (0.54) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL2625570 | 0.77 | SMN1; SMN2 (0.65) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL16480329 | 0.77 | SMN1; SMN2 (0.59) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL22521954 | 0.74 | SMN1; SMN2 (0.64) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL220198 | 0.72 | KMT2A (0.51) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL1947779 | 0.72 | YTHDF2 (0.50) | MEN1KMT2ASMN1; SMN2HTTTP53 | |
| SCHEMBL5307016 | 0.72 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2HTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778276-B | Compounds as SHP2 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-4056563-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2022-09-14 | — | — | EP | disclosed |
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-03-24 | — | — | US | disclosed |
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2021-12-23 | — | — | US | disclosed |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| CN-112778276-A | Compound as SHP2 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| EP-3310779-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | MEN1 1968/4885KMT2A 1232/4885SMN1; SMN2 3724/4885 |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN5 | MEN1 1460/4885KMT2A 710/4885SMN1; SMN2 2340/4885 |
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | PTPN1, PTPN5, PTPN2 | MEN1 3564/4885KMT2A 866/4885SMN1; SMN2 2628/4885 |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | MEN1 4216/4885KMT2A 3837/4885SMN1; SMN2 4754/4885 |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | MEN1 1968/4885KMT2A 1232/4885SMN1; SMN2 3724/4885 |
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN7 | MEN1 1062/4885KMT2A 1900/4885SMN1; SMN2 3004/4885 |
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | MEN1 860/4885KMT2A 983/4885SMN1; SMN2 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.